.. ..., , ..
. .. . , . , ...,
: 2019 .
:
- -
-
--
-
-
-
NPHS1
NPHS2
PLCE1 1
TRPC-6 - 6
NEPH1 1
CD2AP CD2-
ZO-1 (zonula occludens 1)
Myo1E M IE
WT-1 1
LMX1B LIM 1 (LIM homeobox transcription factor 1, beta)
SMARCAL1 , ; - , 1
INF2 2.
:
1. 酅.....5
2. , . .6
3. , .. .5
4. .....7
5. 腅.....8
6. ..9
7. .. 9
7.1. - ȅ.. . 9 7.2. ȅ.......9
7.3. - .10
7.4. ȅ. .11
7.5. - ȅ... .11
7.6. х... .13
8. 煅.....13
9. ....14
,
1, 2 (.1), , , (.2).
1. ( KDIGO)
|
|
1 | , , | ||
2 | , , , , | , . , | , , |
() | , - , , . |
2.
( KDIGO)
, | |
- | , , |
D |
, :
2. 3. ,
1. () , - , ( ) (), . (). |
76,6 % () . . 2:1 , . . |
3. 4. ,
() - . , , , . |
(): o NPHS1, NPHS2, TRCP6, CD2AP, ACTN4, INF2, MYH9, MYO1E o PLCE1 o LAMB2 o WT1, LMX1B o SCARB2 o COQ2 o - - SMARCAL1 |
, : , : - : : |
: : in vivo in vitro - . - h2, IL-4 IL-13. NFkB . NFkB IkB, . - . : , . 66% . . , . - . |
4. 5.
|
|
. 30-70% . , , . . . , - . (20-30%), . : , . |
5.1. 2. - (). .
6.
: , ( 3- ), . . - . - . : . : . |
|
|
5.2. 3. (H)
, (. 4) .
.
6.
6.1. 4. , (). - - .(1)
6.2. 5. . (.4) ().
6.3. 6. , , ().
7.
7.1. - ()
7. .
7. -
8. () 12 (1B). 9. (1B) 60 /2/24 2 //24, 60 /24 (1D). 10. 4-6 (1C), ( ), 40 /2 1,5 / ( 40 ) (1D) 25 , (1B). 11. (2D). |
7.2. .
7.2.1. - .
8. -
12. 60 /2 2 / ( 60 /24) , 3 (2D). 13. 40 /2 1,5 / ( 40 ) 4 (2C). |
7.2.2. - - - .
9. - - -
14. , 3 , 3 (2C). 15. , , (2D). 16. , , (2D). 17. , , , (2C). |
|
|
7.3 - .
7.3.1. - - - .
10. - - -
18. - , (1B). 19. (1B) (2C) - . 20. 2 //24 8-12 ( 168 /) (2C). 21. , (2D). 22. 0,1-0,2 //24 8 ( 11,2 /) (2C). 23. (2D). |
7.3.2. - - - .
11. - - - .
24. (1) 2,5 / (2B) 12 (2C), . |
7.3.3. ( ) - - - .
12. ( ) - - - (1)
25. 4-5 //24 (2C). 26. 0,1//24 (2D). 27. () (). 28. 12 , (2C). |
7.3.4. - - - .
13. - - - (2)
29. 1200 /2/24 720 /2 12 , (2C). |
7.3.5. - - - .
14. - - -
30. , , - , , (2C). |
31. - (2C).
32. - (1B).
7.4. .
33. ():
|
|
;
;
, .
7.5. -
34. : 8 , - (2D).
35. ():
;
;
.
15.
36. (1B).
37. 6 , , (2C).
38. 12 , 6 (2C).
39. (2D).
40. (1B).
41. - () :
, : 41. (2D), (2D) (2D) , . 42. (2B). 43. (2C): (2D); , (2D);
(2D) |
7.6.
44. ():
- .
, , .
, 1 //24 (<20 /4) 2 / (<40 ).
, - .
, , , 3-6 .
, , .
, , , , , . .
, , , , , . . . |
1. . / . . /.. , . , . , . , . , . , . , . , . , . . .: 2006; 336.
2. . / . . , .. , .. . .: - 2010.
3. . / . .. , 3- . .: 2011;696.
4. : . .. , .. . .: 2009; 300.
5. .
|
6. . . .. .: 2010; 683.
7. Davin J.-C., Rutjes N.W. Nephrotic Syndrome in Children: From Bench to Treatment. International Journal of Nephrology. 2011;8:1-6.
8. Dorresteijn E.M., Kist-van Holthe J.E., Levtchenko E.N. et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatric Nephrology, 2008; 23(11):20132020.
9. Eddy A.A., Symons J.M. Nephrotic syndrome in childhood. Lancet 2003; 362(9384):629639.
10. Hinkes B.G., Mucha B., Vlangos C.N. et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics, 2007; 119(4): e907e919.
11. Hodson E.M., Willis N.S., Craig J.C. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database of Systematic Reviews, 2008; 1: Article ID CD002290.
12. Hodson E.M., Willis N.S., Craig J.C. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database of Systematic Reviews, 2010;11: Article ID CD003594.
13. Kimata H., Fujimoto M., Furusho K. Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome. European Journal of Immunology, 1995; 25(6): 14971501.
14. Lai K.W., Wei C.L., Tan L.K. et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats Journal of the American Society of Nephrology, 2007; 18(5):14761485.
15. Machuca E., Benoit G., Antignac C., Genetics of nephrotic syndrome: connecting molecular genetics to podocyte physiology. Human Molecular Genetics, 2009;18(R2): R185R194.
16. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney International. 1978;13(2):159-165.
17. Niaudet P. Steroid-sensitive nephrotic syndrome in children in Paediatric Nephrology. /E.D. Avner, W.E. Harmon and P. Neasden, Eds. 2004; 543556, Lippincott Williams and Wilkins, Philadelphia, Pa, USA.
18. Siegel N.J., Gur A., Krassner L.S., Kashgarian M. Minimal-lesion nephrotic syndrome with early resistance to steroid therapy. J Pediatr 1975;87(3):377380.
19. Yap H.K., Cheung W., Murugasu B.,. Sim S.K, Seah C.C., Jordan S.C. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. Journal of the American Society of Nephrology, 1999;10(3):529537.